sent_id	id1	id2	out1	out2	label	score
167	237	612	the ABC Irritability subtest score	treatment-related side effects	0	0.0014103584690019488
421	655	105	attitudes, knowledge and skills in EBM	knowledge	0	0.14804719388484955
714	1862	923	pain severity and knee range of motion (ROM)	pain	0	0.04208773002028465
598	913	248	instrumental birth	intervention during labour and delivery	0	0.11920291185379028
680	1812	680	the total stool weight in grams during hospitalization	the mean stool weight during hospital stay	1	0.14033624529838562
22	33	982	composite death, reinfarction, stroke, or new myocardial ischemia	revascularization-procedures	0	0.006692850962281227
140	207	525	educational achievement and anaemia	economic cost	0	0.002182716503739357
248	1619	951	sucrose/pacifier effect on pain reduction	crying time	0	0.2018132209777832
407	650	170	trough forced expiratory volume in one second (FEV 1 ) at 24 h post-dose after 14 days	24-h bronchodilation	0	0.17328819632530212
56	1074	839	the proportion of patients with plasma HIV-1 RNA levels <200 copies/mL at week 24	virologic suppression	0	0.5774953365325928
54	1074	837	the proportion of patients with plasma HIV-1 RNA levels <200 copies/mL at week 24	virologic suppression	0	0.5774953365325928
200	1273	121	the percentage of patients who had a CSTE	CSTEs	1	0.6076632142066956
142	1198	919	health care costs and utilization rates	A COPD-related cost offset	0	0.29421496391296387
166	237	611	the ABC Irritability subtest score	The ABC-C Irritability Subscale scores	1	0.1919327825307846
559	861	932	changes in lifestyle according to established goals	inclusion rate	0	0.0010322310263291001
106	161	854	HbA1c, lipid levels, blood pressure, BMI after 24 months of follow-up	Glycated hemoglobin A1c	0	0.6926419734954834
391	632	216	Physical Function	function	1	0.3486451804637909
473	1601	395	costs per quality adjusted life years (cost/QALY)	tube dependency	0	0.005554925184696913
69	396	800	force platform variables PVF and impulse, the validated HCPI and the use of rescue NSAIDs	NSAID use	0	0.02931223064661026
166	237	611	the ABC Irritability subtest score	the VAS	0	0.010986942797899246
249	424	546	The Insomnia Severity Index (ISI) 32	sleep onset latency	0	0.007577241398394108
683	1816	851	pain and disability	disability	0	0.14804719388484955
258	1328	268	DFS	DFS improvement	1	0.3208213150501251
530	1610	300	improvement in attention scores for the intervention group	the other cognitive outcomes	0	0.005911069456487894
446	1502	1100	sUA < 6.0 mg/dL at final visit	efficacious	0	0.08509904891252518
556	859	962	blood pressure control	The control rate	1	0.531209409236908
610	928	392	child body mass index (BMI) z-score	moderate-to-vigorous physical activity	0	0.0015978454612195492
588	896	407	PK parameters and safety and tolerability	absorbed rapidly	0	0.04208773002028465
540	826	505	the p27 antigen analysis of serum samples	age-related resistance to infection with a virulent FeLV challenge	0	0.03514484688639641
21	33	981	composite death, reinfarction, stroke, or new myocardial ischemia	The primary combined endpoint of death, recurrent MI and unstable angina	0	0.42250463366508484
596	913	246	instrumental birth	instrumental birth	1	0.9883127808570862
80	126	835	changes in pain as measured on a verbal rating scale from 0 to 10 during a flexion-extension range of motion evaluation and changes in disc height as measured on CT scans	pain	0	0.28140559792518616
65	108	800	force platform variables PVF and impulse, the HCPI and rescue NSAIDs	Quality of life VAS	0	0.0017007224960252643
405	1483	187	the Premature Infant Pain Profile (PIPP ) 48 49	Facial actions	0	0.10087861865758896
132	1163	192	the number of retrieved oocytes	The incidence of adverse events	0	0.0008559006382711232
148	1205	328	Rate of change in [Na]	rate of study fluid infusion	0	0.020332353189587593
480	1541	593	ETDRS visual acuity recorded in the laboratory, supplemented with a number of secondary lab-based visual function measures	logMAR	0	0.5467381477355957
286	1342	737	"the percentage change in ""average pain for the past 24 hours"" NPRS scores from baseline to weeks 2 through 8"	considered themselves improved (much, or very much)	0	0.005554925184696913
372	607	578	log HbA 1c	glycaemic control	1	0.2018132209777832
206	1274	1033	the incidence of predefined GI AEs	GI safety profiles	1	0.24508501589298248
190	1271	82	change in nutrition knowledge scores, attitudes to healthy eating and acceptability of the intervention by children and teachers	considered it a useful resource	0	0.022977370768785477
583	1678	639	the time course of the corrected colonisation index	frequently colonised body sites	0	0.03308597952127457
305	1362	94	Self-reported knee-specific stiffness, pain and function	All revisions	0	0.006289901677519083
124	190	185	all-cause mortality over 3 years	the rate of exacerbations	0	0.0009697519708424807
630	942	206	the EQ-5D utility	participation	0	0.007121428847312927
8	1016	102	blood pressure	systolic BP	0	0.3775406777858734
532	1617	175	the frequency of decision by the specialist to offer a follow-up outpatient appointment, patient satisfaction (Ware Specific Questionnaire), wellbeing (SF12) and enablement (PEI), numbers of tests, investigations, procedures and treatments	response rate	0	0.004331502132117748
79	126	834	changes in disc height as measured on CT scans	low back pain	0	0.0035936026833951473
499	852	849	a reduction in depression	GDS scores	1	0.665410578250885
391	632	216	WOMAC Pain, Physical Function and Total scores	quality of life	0	0.0029810331761837006
437	682	589	trial feasibility, defined by randomization of >25% of eligible patients, delivery of >75% of the prescribed CRRT dose, and follow-up of >95% of patients to 60 days	vasopressor requirements	0	0.0031726828310638666
659	1962	886	trough FEV 1 after 12 weeks of treatment (average of the 23 h 10 min and 23 h 45 min post-dose values assessed on the morning of Day 85)	bronchodilation	0	0.027585284784436226
56	273	1001	Treatment Alliance Scale (TAS) 40 and Client Satisfaction Questionnaire (CSQ) 44 	alliance	0	0.1919327825307846
411	651	684	the PHQ-9	acceptable	0	0.22270014882087708
233	389	482	comparison of the change from baseline to end of 12 weeks between simvastatin and fenofibrate	HDLP number	0	0.09009299427270889
703	1839	1028	1) defecation frequency > 3/week; 2) normalization of stool consistency; 3) no more painful defecation; 4) absence of abdominal or rectal palpable mass at physical examination	Improvement of hard stool consistency to soft stool consistency	0	0.02595735527575016
311	513	200	Early Treatment Failure (ETF); Late Clinical Failure (LCF); Late Parasitological Failure (LPF); Adequate Clinical and Parasitological Response (ACPR) 18	compliance	0	0.0017007224960252643
141	207	528	educational achievement and anaemia	programme costs	0	0.0017007224960252643
69	396	800	the use of rescue NSAIDs	Quality of life VAS	0	0.005911069456487894
389	1697	714	"the change in IOP from baseline to week 4 at 8 a.m. and 4 p.m. for the per protocol (PP) population using a ""worse eye"" analysis"	Least squares mean IOP changes	1	0.1919327825307846
226	1288	970	mortality	the evidence-based key interventions and organized care were more applied	0	0.0023231625091284513
428	1821	207	participation in the Link-Up Study, through attendance at a biospecimen collection site to provide a blood sample and giving written consent to participate, including use of blood samples for genetic and other research	the response rate	1	0.02595735527575016
581	1668	768	the Freezing of Gait Questionnaire	stride length	0	0.010986942797899246
570	880	257	retention in treatment, which was defined as the number of weeks that patients remained in the study before being discharged	the rates of opioid-positive urine tests	0	0.012431650422513485
705	1839	1031	1) defecation frequency > 3/week; 2) normalization of stool consistency; 3) no more painful defecation; 4) absence of abdominal or rectal palpable mass at physical examination	hard stools	0	0.020332353189587593
596	913	246	instrumental birth	breastfeeding initiation	0	0.0029810331761837006
476	1601	398	costs per quality adjusted life years (cost/QALY)	the willingness to pay threshold for 1 additional QALY	0	0.08509904891252518
301	507	873	the change from baseline to 52 weeks of carotid arterial wall volume, reflecting plaque burden, as measured by carotid cardiovascular magnetic resonance	the respective volumes	0	0.5467381477355957
308	513	196	Early Treatment Failure (ETF); Late Clinical Failure (LCF); Late Parasitological Failure (LPF); Adequate Clinical and Parasitological Response (ACPR) 18	the recrudescence cases	0	0.1919327825307846
492	1952	18	Kinetic force platform gait analysis (PVF BW )	the PVF BW	1	0.9284088015556335
96	141	192	begin oral intake	time to start oral intake	1	0.4843800961971283
223	389	472	comparison of the change from baseline to end of 12 weeks between simvastatin and fenofibrate	total cholesterol	0	0.2018132209777832
433	1494	47	Number of headache days over a 12 week period (item A MIDAS questionnaire)	the number of migraine like headaches at 12 weeks	1	0.02595735527575016
752	1936	54	changes compared to baseline observed after 4 weeks (40 sessions) of treatment, in parallel groups, on (1) Aberrant Behavior Checklist–Community (ABC) total score and subscale scores, based on the parent's or primary caretaker's rating, (2) Autism Treatment Evaluation Checklist (ATEC) total score and subscale scores, based on the parent's or primary caretaker's rating, and (3) Clinical Global Impression–Improvement (CGI) scale for changes in overall functioning and subscales, as rated by the parent or primary caretaker and also as rated separately by the treating physician (without knowledge of the parental ratings)	overall functioning	0	0.031143832951784134
635	954	620	the serum phosphorus at 12 weeks	serum phosphorus concentration	1	0.7772998809814453
350	1429	734	the performance of the trial according to the revised CONSORT statement	adherence	0	0.13296423852443695
421	655	105	attitudes, knowledge and skills in EBM	self-reported critical appraisal skills	0	0.29421496391296387
219	1284	689	the volume of blood loss between T1 and T4	PRBC transfusion	0	0.07585818320512772
597	913	247	caesarean birth	likely to have continuous electronic fetal monitoring	0	0.031143832951784134
596	913	246	relative risk	caesarean birth	0	0.1919327825307846
596	913	246	induction of labour	induction	1	0.7431679368019104
683	1816	851	pain and disability	disability	0	0.14804719388484955
65	108	800	PVF	PVF	1	0.985042929649353
457	1518	544	pain catastrophising	efficacy	0	0.06754668802022934
683	1816	851	pain	disability	0	0.012431650422513485
195	1983	82	nutrition knowledge	considered it a useful resource	0	0.08035746961832047
665	990	954	the mean number of oocytes retrieved	painful	0	0.0011695101857185364
291	494	629	the disclosure rate of abuse by women who were identified by the VAWS tool during the three screening sessions compared to those in the interview group	the identification rate	1	0.037326883524656296
587	891	501	improved PFS for the maintenance phase	promising PFS	1	0.11279541254043579
347	1428	537	pedometer step counts (Omron HJ-109E Step-O-Meter)	several variables of self-reported physical activity	0	0.00247262348420918
71	396	802	the validated HCPI	veterinary assessment	0	0.04208773002028465
529	1610	299	improvement in attention scores for the intervention group	learning mean score	0	0.006289901677519083
607	1719	705	the occurrence of any surgical-site infection within 30 days of surgery	surgical-site infection	1	0.8519527316093445
187	1271	79	change in nutrition knowledge scores	Mean total nutrition knowledge score	1	0.6791787147521973
367	600	33	patient-perceived recovery (PPR) 10	functional limitations	0	0.031143832951784134
605	1717	365	school rule infractions	absenteeism	0	0.02161533571779728
646	970	644	Difference in plasma bone marker concentration between treatment groups	markers of bone formation or resorption	0	0.2120688110589981
227	389	476	comparison of the change from baseline to end of 12 weeks between simvastatin and fenofibrate	LDLP size	0	0.004070138093084097
719	1862	928	knee range of motion (ROM)	the necessary ROM for discharge	1	0.08509904891252518
59	1078	407	the rate of response to PRGF	pain	0	0.020332353189587593
295	501	311	disease-free survival (DFS) at three years	neutropenia	0	0.00031503866193816066
156	1257	559	RDQ	TSK	0	0.02595735527575016
743	1898	1088	3 types of acute-care services, defined as hospitalizations, partial hospitalizations, and visits to emergency departments (EDs)	clinical and economic outcomes	0	0.01798621006309986
647	1782	882	Trough FEV 1 after 12 weeks of treatment	The overall rates of AEs	0	0.0010322310263291001
240	406	264	a dichotomous measure (occurrence of low back pain)	likely to be older	0	0.0029810331761837006
704	1839	1029	1) defecation frequency > 3/week; 2) normalization of stool consistency; 3) no more painful defecation; 4) absence of abdominal or rectal palpable mass at physical examination	painful defecation	0	0.016914913430809975
267	1333	353	sexual activity	sexual activity	1	0.9755768775939941
465	797	379	change in EPIC urinary HRQOL domain summary score at 3 months after the completion of RT (ΔEPIC-U 3mo )	PSA failure	0	0.0026316740550100803
598	913	248	postpartum haemorrhage	safe	0	0.024423088878393173
97	1122	89	days alive and off assisted breathing	FEV1/FVC	0	0.0009110512328334153
378	884	261	ACR 50 improvement	scores on the Health Assessment Questionnaire	0	0.01912403665482998
457	1518	544	pain catastrophising	pain acceptance	0	0.01912403665482998
424	660	861	clinical response at the test-of-cure visit (14–35 days after therapy) for the m-mITT and ME populations	frequently reported adverse events	0	0.0006667023408226669
134	200	462	the change in serum methylmalonic acid (MMA) levels after one month of treatment	the homocysteine level	0	0.0017007224960252643
296	501	312	disease-free survival (DFS) at three years	frequently recorded Grade 3/4 toxicity	0	0.001098731067031622
500	1569	893	change in summary lifestyle score (Prudence Score)	The Prudence Score (10 items)	1	0.6926419734954834
457	1518	544	pain catastrophising	pain catastrophising	1	0.9840936064720154
79	1099	378	body weight	%fat	0	0.11279541254043579
649	974	284	the percent of subjects meeting TR during the initial 30 minutes of treatment	rates of five and six instances within TR	0	0.0446808747947216
687	1833	1069	IPV (Composite Abuse Scale CAS) and depression (Edinburgh Postnatal Depression Scale EPDS)	mental wellbeing mean scores (MCS-SF36	0	0.014957086183130741
82	128	653	absence of parasites and clinical signs on days 14 and 28, and good clinical and biological tolerability	clinical and parasitological response rate	0	0.14804719388484955
390	632	215	Physical Function	Vitality	0	0.022977370768785477
277	1337	66	mortality at 30 days	mortality	1	0.8991213440895081
312	519	150	treatment adherence at and beyond eight sessions	adherence to treatment at and beyond eight sessions	1	0.9525741338729858
366	597	245	a decrease in carer burden in the intervention group three months after receiving the DA	knowledge	0	0.0009110512328334153
416	1489	1064	PCR-corrected adequate clinical and parasitological response (ACPR) on day 28	bilirubin	0	0.005220125894993544
52	102	826	pulmonary or cardiac toxicity	HRQOL scores	0	0.02161533571779728
189	1271	81	change in nutrition knowledge scores, attitudes to healthy eating and acceptability of the intervention by children and teachers	said they 'are currently eating a healthy diet' (39.6%) or 'would try to eat a healthy diet'	0	0.00912563782185316
90	136	791	the hands-on time during the first three minutes of the cardiac arrest	time to defibrillation	0	0.014957086183130741
327	543	636	body weight (kg) and waist circumference (cm)	weight loss	0	0.14033624529838562
316	523	957	morning peak expiratory flow after 4 weeks treatment	morning peak expiratory flow	1	0.665410578250885
384	1463	263	iPTH	the iFGF23 level	0	0.010986942797899246
621	932	925	PDSS	the effectiveness	0	0.2018132209777832
112	166	348	the percentage of patients who reached 25(OH)D levels of 30 ng/ml or above on day 7	serum 25(OH)D	1	0.14033624529838562
374	1445	808	The AIMS2 walking and bending sub-scale	quality of life	0	0.010986942797899246
760	1938	546	reduction in duration of severe pneumonia and pneumonia	nil per oral	0	0.01590639166533947
65	108	800	rescue NSAIDs	NSAID use	1	0.22270014882087708
595	897	566	improvement of GHbA 1c and the SF-36 quality of life score	glycaemic control	0	0.10087861865758896
592	1701	530	intra-operative pain	pain control	0	0.1561049073934555
596	913	246	postpartum haemorrhage	Apgar scores	0	0.0015978454612195492
651	1962	877	trough FEV 1 after 12 weeks of treatment (average of the 23 h 10 min and 23 h 45 min post-dose values assessed on the morning of Day 85)	Trough FEV 1 (LSM ± SEM)	1	0.42250463366508484
170	1912	965	knowledge of labour analgesia, decisional conflict (uncertainty regarding analgesia decision) and anxiety	likely to consider their care providers opinion	0	0.03514484688639641
276	1337	65	cumulative survival without mechanical ventilation or oxygen dependency at 30 days	therapy failure	0	0.07585818320512772
467	797	381	change in EPIC urinary HRQOL domain summary score at 3 months after the completion of RT (ΔEPIC-U 3mo )	biochemical control	0	0.0004878571489825845
168	1912	963	knowledge of labour analgesia	knowledge scores	1	0.622459352016449
226	389	475	comparison of the change from baseline to end of 12 weeks between simvastatin and fenofibrate	both LDLP fractions	0	0.1259227693080902
53	102	827	pulmonary or cardiac toxicity	role- and cognitive-functioning	0	0.005554925184696913
74	112	1073	claim duration (in days) during 12 months follow-up	pain severity	0	0.0006263342220336199
402	646	208	MCS	EPDS score	0	0.027585284784436226
326	534	865	response rates	response rates to a postal health questionnaire	1	0.8670357465744019
549	1630	589	the frequency of fussing and crying of the infants	stooling	0	0.0015978454612195492
379	884	262	ACR 50 improvement	therapeutic responses	0	0.11279541254043579
69	396	800	PVF	Quality of life VAS	0	0.012431650422513485
237	399	1102	biochemically verified 7-day point prevalence smoking abstinence defined as no cigarettes (not even a puff) in the previous 7 days at Week 26, validated using salivary cotinine collected at Week 26	confidence to quit	0	0.00031503866193816066
59	1078	407	the rate of response to PRGF	minor adverse events	0	0.0015011822106316686
237	1965	199	to test the effect of TA on the incidence of IR and VS in patients undergoing elective CPB	levels of soluble tumor necrosis factor receptor	0	0.0006667023408226669
138	1456	912	VC	progression-free survival time	0	0.020332353189587593
384	1463	263	iPTH	the iPTH level	1	0.8438951373100281
108	1588	944	extubated	successfully extubated	1	0.859663724899292
596	913	246	instrumental birth	caesarean birth	0	0.02931223064661026
108	1588	944	extubated	reintubated	0	0.004331502132117748
178	1243	322	the change relative to baseline in the multiple sclerosis functional composite score (MSFC)	incidence of severe and serious events	0	0.0008040859247557819
190	288	365	the number of hospital days after surgery	effective	0	0.008061991073191166
187	1271	79	change in nutrition knowledge scores, attitudes to healthy eating and acceptability of the intervention by children and teachers	Mean total nutrition knowledge score	0	0.562176525592804
147	1200	3	Anthropometry at birth	the proportion of stunting	0	0.29421496391296387
529	813	302	the 11-point NRS in patients' daily pain diaries	well tolerated	0	0.01912403665482998
385	1463	264	the differences in the levels of iFGF23 and iPTH after each treatment period	the levels of iFGF23	0	0.16451646387577057
707	1843	664	Weight-for-age Z-score	Mean duration of follow-up	0	0.004331502132117748
729	1882	216	whether or not a survey recipient responded	response rates	1	0.29421496391296387
87	133	160	HbA1c	Attendance at yoga classes	0	0.0006667023408226669
406	1483	188	the Premature Infant Pain Profile (PIPP ) 48 49	powerfully	0	0.01798621006309986
118	170	134	The frequency, duration and severity of exacerbations	dyspnea	0	0.06371499598026276
218	383	993	PCR-adjusted 42-day cure rates after starting treatment	cure rates	1	0.22270014882087708
494	770	539	the time until shock reversal	IL-2	0	0.007577241398394108
350	1429	734	the performance of the trial according to the revised CONSORT statement	completion rate	0	0.23370636999607086
614	929	228	the percentage of days on which the prescribed dose of medication was taken, measured objectively over 12 weeks with an electronic medication-monitoring device (TrackCap, Aardex, Switzerland)	objectively measured medication adherence	1	0.7772998809814453
318	1376	1082	The 6MWT	maximum work load	0	0.09534946084022522
249	1619	952	sucrose/pacifier effect on pain reduction	effective	0	0.3923368752002716
276	1337	65	cumulative survival without mechanical ventilation or oxygen dependency at 30 days	crossover	0	0.0038244836032390594
283	486	346	recurrence	The final pain score per patient	0	0.03963883966207504
109	210	854	glycated hemoglobin A1c	Glycated hemoglobin A1c	1	0.9896718263626099
45	77	797	VC	The efficacy	0	0.23370636999607086
432	978	484	response rate based on a 20% improvement in WOMAC pain scores	The response rates (20% reduction in WOMAC pain)	1	0.9362850189208984
672	1802	1021	The throughput times length of ED stay (LOS)	times	1	0.16451646387577057
595	1707	535	CR	emotional functioning	0	0.013222821988165379
654	980	99	BMD	hip BMD	1	0.4378235340118408
331	1402	131	the patient assessment of spinal pain (100-mm VAS), patient global assessment of disease activity (100-mm VAS), and the Bath Ankylosing Spondylitis Functional Index (100-mm VAS)	BASDAI	0	0.022977370768785477
304	1362	93	Self-reported knee-specific stiffness, pain and function	overall health	0	0.0013250223128125072
664	990	953	the mean number of oocytes retrieved	live birth	0	0.008061991073191166
195	304	125	The median RTDI	OS	0	0.002800926798954606
452	707	1068	health-related quality of life (HRQoL)	6-minute walking distance	0	0.01912403665482998
117	170	133	The frequency, duration and severity of exacerbations	frequency	0	0.3775406777858734
45	77	797	VC	IPF	0	0.03514484688639641
96	1122	88	days alive and off assisted breathing	forced vital capacity (FVC	0	0.0008040859247557819
596	913	246	Apgar scores less than 8	instrumental birth	0	0.04208773002028465
123	1150	622	the primary care practices' mean levels of HbA1c, cholesterol and BP, and numbers of patients with recorded foot inspections in the previous calendar month	process of diabetes care	0	0.006289901677519083
276	1337	65	cumulative survival without mechanical ventilation or oxygen dependency at 30 days; mortality at 30 days; therapy failure; crossover rate; and persisting pulmonary problems defined as oxygen dependency or still being on a ventilator at 30 days	survival without supplemental oxygen or on ventilator	0	0.5156199336051941
451	1512	1052	more frequently interrupted MARS sessions without anticoagulation	patency of the extracorporeal circuit	0	0.016914913430809975
402	646	208	the EPDS (a 10-item scale developed for use in the postnatal period, in which a score ≥ 13 identifies probable depression 33	MCS	0	0.024423088878393173
49	1808	336	the mean change in self-reported symptoms of depression as measured on the BDI	The estimated sample size for a full trial	0	0.002182716503739357
